Pharmacokinetic evaluation of fluconazole in critically ill patients

Bibliography

• Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24:10-27
   PubMed Web of Science ®Google Scholar
• Charlier C, Hart E, Lefort A, Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410
   PubMed Web of Science ®Google Scholar
• Thaler F, Bernard B, Tod M, Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother 1995;39:1154-6
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009;48:503-35
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Epidemiology of candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Kollef MH, Arnold H, Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010;10:150-4
   PubMed Web of Science ®Google Scholar
• Labelle AJ, Micek ST, Roubinian N, Treatment-related risk factors for hospital mortality in candida bloodstream infections. Crit Care Med 2008;36:2967-72
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-17
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rello J, Marshall J, International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9
   PubMed Web of Science ®Google Scholar
• Holley A, Dulhunty J, Blot S, Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009;33:554, e1-7
   PubMedGoogle Scholar
• Pfaller MA, Diekema DJ, Jones RN, International surveillance of bloodstream infections due to candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9
   PubMed Web of Science ®Google Scholar
• Pereira GH, Muller PR, Szeszs MW, Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans candida species. Med Mycol 2010;48:839-42
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34:857-63
   PubMed Web of Science ®Google Scholar
• Klingspor L, Tornqvist E, Johansson A, Prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004;36:52-5
   PubMed Web of Science ®Google Scholar
• Trick WE, Fridkin SK, Edwards JR, National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the united states during 1989 – 1999. Clin Infect Dis 2002;35:627-30
   PubMed Web of Science ®Google Scholar
• Marchetti O, Bille J, Fluckiger U, Epidemiology of candidemia in swiss tertiary care hospitals: secular trends, 1991 – 2000. Clin Infect Dis 2004;38:311-20
   PubMed Web of Science ®Google Scholar
• Playford EG, Nimmo GR, Tilse M, Increasing incidence of candidaemia: long-term epidemiological trends, queensland, australia, 1999 – 2008. J Hosp Infect 2010;76:46-51
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63
   PubMed Web of Science ®Google Scholar
• Playford EG, Marriott D, Nguyen Q, Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans candida spp. Crit Care Med 2008;36:2034-9
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Fuursted K, Gahrn-Hansen B, Semi-national surveillance of fungaemia in denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008;14:487-94
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Fuursted K, Gahrn-Hansen B, Seminational surveillance of fungemia in denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005;43:4434-40
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Steele-Moore L, Twelve years of fluconazole in clinical practice: global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of candida. Clin Microbiol Infect 2004;10:11-23
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43:S3-14
   Web of Science ®Google Scholar
• Chow JK, Golan Y, Ruthazer R, Factors associated with candidemia caused by non-albicans candida species versus candida albicans in the intensive care unit. Clin Infect Dis 2008;46:1206-13
   PubMed Web of Science ®Google Scholar
• Chow JK, Golan Y, Ruthazer R, Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008;36:1993-8
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010;54:3149-54
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of candida glabrata: an assessment from the ARTEMIS DISK global antifungal surveillance program. Diagn Microbiol Infect Dis 2010;67:162-71
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-45
   PubMed Web of Science ®Google Scholar
• Rajagopalan P, Pelz RK, Lipsett PA, Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit. Pharmacotherapy 2003;23:592-602
   PubMed Web of Science ®Google Scholar
• Zhou W, Nightingale CH, Davis GA, Absolute bioavailability of fluconazole suspension in intensive care unit patients. J Infect Dis Pharmacother 2001;5:27-35
   PubMedGoogle Scholar
• Rosemurgy AS, Markowsky S, Goode SE, Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration. J Trauma Inj Infect Crit Care 1995;39:445-7
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Crowe H, Nightingale CH, Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 1995;36:395-401
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Crowe H, Nightingale CH, Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole. Pharmacotherapy 1994;14:502-5
   PubMed Web of Science ®Google Scholar
• Buijk SLCE, Gyssens IC, Mouton JW, Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med 2001;27:115-21
   PubMed Web of Science ®Google Scholar
• Sobel JD, Kauffman CA, McKinsey D, Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. the national institute of allergy and infectious diseases (NIAID) mycoses study group. Clin Infect Dis 2000;30:19-24
   PubMed Web of Science ®Google Scholar
• Wong SF, Leung MP, Chan MY. Pharmacokinetics of fluconazole in children requiring peritoneal dialysis. Clin Ther 1997;19:1039-47
   PubMed Web of Science ®Google Scholar
• Debruyne D, Ryckelynck JP. Fluconazole serum, urine, and dialysate levels in CAPD patients. Perit Dial Int 1992;12:328-9
   PubMed Web of Science ®Google Scholar
• Bergner R, Hoffmann M, Riedel KD, Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006;21:1019-23
   PubMed Web of Science ®Google Scholar
• Kishino S, Koshinami Y, Hosoi T, Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration. Ther Drug Monit 2001;23:4-8
   PubMed Web of Science ®Google Scholar
• Muhl E, Martens T, Iven H, Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000;56:671-8
   PubMed Web of Science ®Google Scholar
• Scholz J, Schulz M, Steinfath M, Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient. J Mol Med 1995;73:145-7
   PubMed Web of Science ®Google Scholar
• Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 1997;40:695-700
   PubMed Web of Science ®Google Scholar
• Yagasaki K, Gando S, Matsuda N, Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 2003;29:1844-8
   PubMed Web of Science ®Google Scholar
• Wolter K, Marggraf G, Dermoumi H, Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD) in a single patient. Eur J Clin Pharmacol 1994;47:291-2
   PubMed Web of Science ®Google Scholar
• Blanchet B, Jullien V, Vinsonneau C, Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008;47:635-54
   PubMed Web of Science ®Google Scholar
• Boucher BA, King SR, Wandschneider HL, Fluconazole pharmacokinetics in burn patients. Antimicrob Agents Chemother 1998;42:930-3
   PubMed Web of Science ®Google Scholar
• Honiden S, McArdle JR. Obesity in the intensive care unit. Clin Chest Med 2009;30:581-99
   PubMed Web of Science ®Google Scholar
• Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007;27:1081-91
   PubMed Web of Science ®Google Scholar
• Cohen LG, DiBiasio A, Lisco SJ, Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy 1997;17:1023-6
   PubMed Web of Science ®Google Scholar
• Garey KW, Pai MP, Suda KJ, Inadequacy of fluconazole dosing in patients with candidemia based on infectious diseases society of america (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007;16:919-27
   PubMed Web of Science ®Google Scholar
• Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999;43:2116-20
   PubMed Web of Science ®Google Scholar
• Louie A, Drusano GL, Banerjee P, Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998;42:1105-9
   PubMed Web of Science ®Google Scholar
• Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006;20:679-97
   PubMed Web of Science ®Google Scholar
• Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003;47:1179-86
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Yu VL, Morris AJ, Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005;49:3171-7
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007;51:3599-604
   PubMed Web of Science ®Google Scholar
• Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51:35-9
   PubMed Web of Science ®Google Scholar
• Baddley JW, Patel M, Bhavnani SM, Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008;52:3022-8
   PubMed Web of Science ®Google Scholar
• Shin JH, Kee SJ, Shin MG, Biofilm production by isolates of candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002;40:1244-8
   PubMed Web of Science ®Google Scholar
• Lewis RE, Kontoyiannis DP, Darouiche RO, Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of candida catheter-related bloodstream infection. Antimicrob Agents Chemother 2002;46:3499-505
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J, Antifungal susceptibility of candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46:1773-80
   PubMed Web of Science ®Google Scholar
• Martinez LR, Fries BC. Fungal biofilms: relevance in the setting of human disease. Curr Fungal Infect Rep 2010;4:266-75
   PubMedGoogle Scholar
• Gafter-Gvili A, Vidal L, Goldberg E, Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008;83:1011-21
   PubMed Web of Science ®Google Scholar
• Playford EG, Lipman J, Sorrell TC. Management of invasive candidiasis in the intensive care unit. Drugs 2010;70:823-39
   PubMed Web of Science ®Google Scholar
• Playford EG, Webster AC, Sorrell TC, Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006;57:628-38
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. candidemia study group and the national institute. N Engl J Med 1994;331:1325-30
   PubMed Web of Science ®Google Scholar
• Phillips P, Shafran S, Garber G, Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16:337-45
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Darouiche RO, Abi-Said D, Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72
   PubMed Web of Science ®Google Scholar
• Abele-Horn M, Kopp A, Sternberg U, A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic candida infections in intensive care patients. Infection 1996;24:426-32
   PubMed Web of Science ®Google Scholar
• Rex JH, Pappas PG, Karchmer AW, A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82
   PubMed Web of Science ®Google Scholar
• Rex JH, Pappas PG, Karchmer AW, A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8
   PubMed Web of Science ®Google Scholar
• Diaz M, Negroni R, Montero-Gei F, A pan-american 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. pan-american study group. Clin Infect Dis 1992;14:S68-76
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Larsen RA, Chiu J, A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. california collaborative treatment group. N Engl J Med 1991;324:580-4
   PubMed Web of Science ®Google Scholar
• Voss A, de Pauw BE. High-dose fluconazole therapy in patients with severe fungal infections. Eur J Clin Microbiol Infect Dis 1999;18:165-74
   PubMed Web of Science ®Google Scholar
• Garbino J, Lew DP, Romand JA, Prevention of severe candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002;28:1708-17
   PubMed Web of Science ®Google Scholar
• Crerar-Gilbert A, Boots R, Fraenkel D, Survival following fulminant hepatic failure from fluconazole induced hepatitis. Anaesth Intensive Care 1999;27:650-2
   PubMed Web of Science ®Google Scholar
• Albert SG, DeLeon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Crit Care Med 2001;29:668-70
   PubMed Web of Science ®Google Scholar
• Michaelis G, Zeiler D, Biscoping J, Function of the adrenal cortex during therapy with fluconazole in intensive care patients. Mycoses 1993;36:117-23
   PubMed Web of Science ®Google Scholar
• Magill SS, Puthanakit T, Swoboda SM, Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrob Agents Chemother 2004;48:2471-6
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Kontoyiannis DP, Huls C, Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995;172:599-602
   PubMed Web of Science ®Google Scholar
• Gussenhoven MJ, Haak A, Peereboom-Wynia JD, Stevens-johnson syndrome after fluconazole. Lancet 1991;338:120-1
   PubMed Web of Science ®Google Scholar
• Thiyanaratnam J, Cohen PR, Powell S. Fluconazole-associated stevens-johnson syndrome. J Drugs Dermatol 2010;9:1272-5
   PubMed Web of Science ®Google Scholar
• Udy AA, Putt MT, Shanmugathasan S, Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents 2010;35:606-8
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, Boots RJ, Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49:1-16
   PubMed Web of Science ®Google Scholar